Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth...
28 insider purchases on record · latest filing 2025-08-20.
Insiders have also filed 41 sale transactions at GOSS.